GLP-1s beyond weight loss: What tirzepatide and semaglutide are doing to metabolism, inflammation, and longevity risk

What GLP-1s actually are

Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut in response to eating. It signals the pancreas to release insulin, tells the stomach to slow gastric emptying, and signals the brain to reduce appetite. GLP-1 receptor agonists are synthetic analogs that mimic and amplify this signal. They bind to GLP-1 receptors throughout the body and activate them more potently and for longer than the natural hormone does.

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. Tirzepatide’s dual mechanism produces greater weight loss in clinical trials, with some trials showing 20-22% body weight reduction at higher doses. Both work. Tirzepatide works more.

The effects beyond the scale

Cardiovascular. The SELECT trial, a large randomized controlled trial of semaglutide 2.4 mg in adults with obesity and established cardiovascular disease, found a 20 percent reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) compared to placebo over a median of 34 months. Critically, the participants did not have diabetes. The cardiovascular benefit was not mediated entirely through blood glucose control or weight loss. GLP-1 receptors in the heart, endothelial cells, and atherosclerotic plaques appear to produce direct anti-inflammatory and anti-atherogenic effects.

Neurological. GLP-1 receptors are expressed in the hippocampus, cortex, and brainstem. Ongoing trials are examining semaglutide for Alzheimer’s disease (EVOKE trial), Parkinson’s disease, and addiction. Early data is promising for each. The mechanism involves reduced neuroinflammation, improved insulin sensitivity in brain tissue, and direct neuroprotective signaling. Clinical application in these areas is years away, but the biological rationale is serious.

Kidney and liver. Semaglutide received FDA approval for reducing the progression of chronic kidney disease in 2024, the first drug to do so since a previous generation of therapies. The FLOW trial showed a significant reduction in kidney failure events. Fatty liver disease (metabolic dysfunction-associated steatohepatitis) also responds to GLP-1s, with tirzepatide achieving histological resolution in a majority of patients in the SURMOUNT-NASH trial.

The muscle loss problem nobody is talking about enough

GLP-1s produce weight loss by reducing caloric intake. The body, when in significant caloric deficit, loses both fat and lean mass. Clinical trial data shows that roughly 25 to 40 percent of the weight lost on GLP-1 therapy is lean mass, not fat. For a person who loses 20 kg on semaglutide, five to eight of those kilograms may be muscle and bone.

This matters significantly for midlife adults. Sarcopenia (age-related muscle loss) is already accelerating. Adding pharmacologically induced muscle loss on top of that is a longevity liability that is being significantly underemphasized in the public GLP-1 conversation. The fix is well-established: resistance training throughout the treatment period and high protein intake (1.6 to 2.2 g per kg of body weight daily). These are not nice-to-haves on GLP-1 therapy. They are requirements for preserving long-term function.

The Livium recipe

Tool. GLP-1 medications require a prescription. Hims provides access to Zepbound (tirzepatide) through a telehealth evaluation process. For muscle protection during GLP-1 therapy: a high-quality whey protein isolate supports the elevated protein intake required during caloric restriction to minimize lean mass loss. Creatine monohydrate 5 g daily has supporting evidence for maintaining lean mass during caloric deficit and should be added to any GLP-1 protocol. A DEXA scan before and six months into treatment is the objective way to track whether the weight loss is fat-predominant or lean-mass-predominant.

Behavior. Resistance training three times per week is non-negotiable on GLP-1 therapy if longevity is the goal, not just the scale number. The reduced appetite that GLP-1s produce makes adequate protein intake challenging; prioritize protein at every meal before other macronutrients. Aim for 30 to 40 g of protein per meal. Function Health provides the metabolic and inflammatory baseline markers that make GLP-1 treatment outcomes trackable: fasting insulin, hsCRP, lipid panel, kidney and liver function.

Threshold. GLP-1s are FDA-approved for obesity (BMI above 30) or overweight (BMI above 27) with a weight-related comorbidity. They are not approved for vanity weight loss. The cardiovascular and metabolic benefits are most clearly established in adults with significant obesity and cardiometabolic risk. Adults within the approved indications who have failed lifestyle interventions alone have a legitimate clinical case for these medications. Adults considering GLP-1s primarily for modest weight loss should understand the risk of muscle loss and weigh it against the benefits with a clinician.

Source: Borrelli et al., JCM 2024 — Cardiovascular Protective Properties of GLP-1 Receptor Agonists. CC BY 4.0.

Plan of action

• If you are considering GLP-1 therapy: get a full metabolic baseline first. Fasting insulin, HbA1c, lipid panel, kidney and liver function, and a DEXA scan for lean mass. This baseline makes it possible to track whether the treatment is doing what it should.
• If you are already on a GLP-1: start resistance training immediately if you have not. The muscle loss begins in the first weeks of treatment. It does not wait for you to get around to lifting weights. Prioritize protein at 1.6 to 2.2 g per kg of body weight daily. Add creatine 5 g daily. These three steps are the longevity protocol for GLP-1 users.
• Do not stop GLP-1 therapy without a plan. The SUSTAIN OFF trials showed that most of the weight lost on semaglutide returns within a year of stopping without lifestyle intervention in place. GLP-1 therapy is not a finite course. It is a chronic medication requiring an exit strategy that includes sustainable dietary and exercise habits. Using a food scale and tracking app during treatment builds the dietary awareness that sustains outcomes after dose reduction.
• For GI side effects (nausea, particularly in the first weeks): take the injection before sleep, eat smaller meals, and avoid high-fat foods in the first two to four weeks of each dose increase. The nausea is dose-adjustment related and resolves for most people within two to four weeks at each dose level. Ginger supplements have consistent evidence of reducing nausea and are safe alongside GLP-1 therapy.